6 unknown, 2 not yet recruiting, 2 recruiting, 1 terminated. 8 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 5, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 2 | Terminated 1, Unknown 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Toripalimab: new trials by email Literature Review of Toripalimab trials Research Report on Toripalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma propranolol, Toripalimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol | Phase 1 / Phase 2 | Not yet recruiting | Ting Liu | 49 | 2026-08-01 | 2026-07-27 |
| Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer Toripalimab - SCLC, Extensive Stage, Toripalimab | Not yet recruiting | Fudan University | 1200 | 2026-02-01 | 2025-12-29 | |
| Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 69 | 2025-07-20 | 2025-11-17 |
| Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 47 | 2024-11-30 | 2026-03-03 |
| Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma EP/EC+PD-1 - Toripalimab, First-line Treatment | Phase 2 | Unknown | Sun Yat-sen University | 33 | 2023-02-18 | 2023-03-08 |
| A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status Toripalimab, CRT, SCRT - Toripalimab, Radiation | Phase 3 | Unknown | Zhejiang Cancer Hospital | 174 | 2022-11-01 | 2022-12-30 |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT Radiotherapy plus Toripalimab, Sorafenib - Radiotherapy, Toripalimab | Phase 3 | Terminated | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 36 | 2021-03-02 | 2025-02-26 |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab - Hepatocellular Carcinoma, Bevacizumab | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-01-01 | 2020-11-13 |
| Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial Toripalimab - Nasopharyngeal Carcinoma, Toripalimab | Phase 2 | Unknown | Cancer Hospital of Guangxi Medical University | 40 | 2020-06-28 | 2021-08-20 |
| Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma Toripalimab combine with Rituximab - Diffuse Large B-cell Lymphoma, Rituximab | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2020-06-15 | 2020-06-16 |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) Anlotinib Plus Toripalimab - Gastric Cancer, Immunotherapy | Phase 2 | Unknown | Shanghai Changzheng Hospital | 24 | 2020-02-10 | 2024-07-10 |
Carcinoma, Hepatocellular (1) · Esophageal Squamous Cell Carcinoma (1) · Liver Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Nasopharyngeal Carcinoma (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (5) · Neoplasms by Histologic Type (4) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms, Glandular and Epithelial (3) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Esophageal Diseases (1)
toripalimab (8) · Radiotherapy (3) · Oxaliplatin (2) · Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Etoposide (1) · Fluorouracil (1) · Immunotherapy (1) · Irinotecan (1) · Propranolol (1) · Rituximab (1) · S 1 (combination) (1)
Sun Yat-sen University (4) · Cancer Hospital of Guangxi Medical University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese Academy of Medical Sciences (1) · Fudan University (1) · Shanghai Changzheng Hospital (1) · Ting Liu (1) · Zhejiang Cancer Hospital (1)
China (8)
Fei Gao (1) · Hui Liu (1) · Hui Liu, Professor (1) · Kangshun Zhu, Professor (1) · Yanxia Shi (1)
PMID 11224527, PMID 16382236, PMID 18173375, PMID 30207593, PMID 35623069, PMID 38200410